Novartis AG, said he abandons the late phase clinical trials for a candidate drug treat lung cancer because the trial was unlikely to suit your company.
This entry was posted on 12 November 2009 at 8: 30 pm and is filed under health. Follow any responses to this post through RSS 2.0. you can leave a response or trackback from your own site.
Subscribe to:
Posts (Atom)